S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
66,000% upside on tiny biotech? (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
66,000% upside on tiny biotech? (Ad)
3 Stocks That Flourish In The Fall
2 Must-Have Silicon Companies That Don't Make Microchips
The single greatest medical breakthrough of all time? (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
66,000% upside on tiny biotech? (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
66,000% upside on tiny biotech? (Ad)
3 Stocks That Flourish In The Fall
2 Must-Have Silicon Companies That Don't Make Microchips
The single greatest medical breakthrough of all time? (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
66,000% upside on tiny biotech? (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
66,000% upside on tiny biotech? (Ad)
3 Stocks That Flourish In The Fall
2 Must-Have Silicon Companies That Don't Make Microchips
The single greatest medical breakthrough of all time? (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
66,000% upside on tiny biotech? (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
66,000% upside on tiny biotech? (Ad)
3 Stocks That Flourish In The Fall
2 Must-Have Silicon Companies That Don't Make Microchips
The single greatest medical breakthrough of all time? (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
Small Caps That Have Priced In A Hard Landing For Big Upside
NASDAQ:ALLK

Allakos (ALLK) Price Target & Analyst Ratings

$2.14
-0.03 (-1.38%)
(As of 09/25/2023 ET)
Compare
Today's Range
$2.11
▼
$2.24
50-Day Range
$2.13
▼
$5.55
52-Week Range
$2.02
▼
$8.73
Volume
2.56 million shs
Average Volume
1.05 million shs
Market Capitalization
$186.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.60
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability

Allakos Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 5 Analyst Ratings

Consensus Analyst Price Target

$13.60
535.51% Upside
High Prediction$22.00
Average Prediction$13.60
Low Prediction$7.00
TypeCurrent
9/26/22 to 9/26/23		1 Month Ago
8/27/22 to 8/27/23		3 Months Ago
6/28/22 to 6/28/23		1 Year Ago
9/26/21 to 9/26/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
2 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
7 Hold rating(s)
Sell
0 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
2 Sell rating(s)
Consensus Price Target$13.60$13.60$13.60$66.80
Predicted Upside535.51% Upside135.87% Upside135.87% Upside95.96% Upside
Get Allakos Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ALLK and its competitors with MarketBeat's FREE daily newsletter.


ALLK Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ALLK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Allakos Stock vs. The Competition

TypeAllakosMedical CompaniesS&P 500
Consensus Rating Score
2.80
2.66
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside535.51% Upside1,402.16% Upside628.19% Upside
News Sentiment RatingNeutral News
Neutral News
Positive News

Historical Target Prices and Ratings

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/11/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeHold ➝ Buy$6.00 ➝ $9.00+116.35%
3/7/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingOverweight$7.00+6.87%
3/7/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageOverweight$22.00+307.41%
3/7/2023Piper Jaffray Companies
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageOverweight$22.00+307.41%
1/27/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetEqual Weight$6.00 ➝ $8.00+9.29%
(Data available from 9/26/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












ALLK Price Target - Frequently Asked Questions

What is Allakos's consensus rating and price target?

According to the issued ratings of 5 analysts in the last year, the consensus rating for Allakos stock is Moderate Buy based on the current 1 hold rating and 4 buy ratings for ALLK. The average twelve-month price prediction for Allakos is $13.60 with a high price target of $22.00 and a low price target of $7.00. Learn more on ALLK's analyst rating history.

Do Wall Street analysts like Allakos more than its competitors?

Analysts like Allakos more than other Medical companies. The consensus rating score for Allakos is 2.80 while the average consensus rating score for medical companies is 2.66. Learn more on how ALLK compares to other companies.

Does Allakos's stock price have much upside?

According to analysts, Allakos's stock has a predicted upside of 135.87% based on their 12-month price targets.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:ALLK) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -